ID   MCF-7 TH
AC   CVCL_ZZ16
SY   MCF-7/TH; MCF-7TH; MCF7/TH; MCF7TH; MCF7Th
DR   cancercelllines; CVCL_ZZ16
DR   Wikidata; Q102114500
RX   PubMed=8562478;
RX   PubMed=9815641;
RX   PubMed=10995814;
RX   PubMed=14871996;
CC   Problematic cell line: Contaminated. Shown to be a OVCAR-8 derivative (PubMed=10995814). Originally thought to be a derivative of MCF-7.
CC   Population: Caucasian.
CC   Doubling time: 50.6 hours (PubMed=8562478; PubMed=9815641).
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=8562478).
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1629 ! OVCAR-8
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 5
//
RX   PubMed=8562478;
RA   Wosikowski K., Regis J.T., Robey R.W., Alvarez M., Buters J.T.M.,
RA   Gudas J.M., Bates S.E.;
RT   "Normal p53 status and function despite the development of drug
RT   resistance in human breast cancer cells.";
RL   Cell Growth Differ. 6:1395-1403(1995).
//
RX   PubMed=9815641;
RA   Wosikowski K., Schuurhuis D., Kops G.J.P.L., Saceda M., Bates S.E.;
RT   "Altered gene expression in drug-resistant human breast cancer
RT   cells.";
RL   Clin. Cancer Res. 3:2405-2414(1997).
//
RX   PubMed=10995814; DOI=10.1093/jnci/92.18.1535;
RA   Pirnia F., Breuleux M., Schneider E., Hochmeister M., Bates S.E.,
RA   Marti A., Hotz M.A., Betticher D.C., Borner M.M.;
RT   "Uncertain identity of doxorubicin-resistant MCF-7 cell lines
RT   expressing mutated p53.";
RL   J. Natl. Cancer Inst. 92:1535-1536(2000).
//
RX   PubMed=14871996; DOI=10.1158/1078-0432.CCR-1044-3;
RA   Hu Y.-P., Krishan A., Nie W.-J., Sridhar K.S., Mayer L.D., Bally M.;
RT   "Synergistic cytotoxicity of pyrazoloacridine with doxorubicin,
RT   etoposide, and topotecan in drug-resistant tumor cells.";
RL   Clin. Cancer Res. 10:1160-1169(2004).
//